Myeloma Patients Europe (MPE) will hold a webinar on the generics market in Europe and implications for cancer treatment and care on Monday 30th March from 17:00 – 18:30 CET.

A generic medicine has the same active ingredient as a branded medicine and can be produced after the patent for the branded medicine expires. For example, Revlimid, a “backbone” treatment in myeloma, recently became generic and is marketed by a range of companies under the generic name lenalidomide. Generic medicines are often a lot cheaper than the branded product. 

Generics offer opportunities for cost savings for public budgets and increased access to treatments for patients. At the same time, generics face a lot of challenges such as intense price competition between companies, which can lead manufacturers to withdraw products, or supply chain vulnerabilities.  

This webinar will give the audience a lay introduction into generics and the generics market in Europe. This will be followed by three case studies presented by patient organisations with a focus in Central and Eastern Europe (CEE) which will focus on challenges and opportunities accessing generics from the patient point of view. The webinar will close with a panel discussion with the presenters on opportunities and challenges in the access of generic medication. During this panel discussion, the audience will have the opportunity to ask questions to the panellists.